For the clinical development of IMA901, the lead product in renal cell carcinoma, and the development of other product candidates, immatics has established a network of worldclass research institutes, physicians and highly regarded hospitals all over Europe and in Japan.

We believe that this cooperation with experienced researchers, investigators, physicians and nurses creates the basis for a focused and successful development of our product candidates in the early phase and throughout further clinical development.